Lv1
80 积分 2024-05-13 加入
Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
14天前
已完结
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
15天前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
15天前
已完结
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
16天前
已完结
Computational assessment of the effects of the catheter type on particle–hemodynamics during liver radioembolization
1个月前
已完结
Estimation of Yttrium-90 Distribution in Liver Radioembolization using Computational Fluid Dynamics and Deep Neural Networks
1个月前
已完结
Efficacy and features of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: a narrative review
2个月前
已关闭
Comparison between resin and glass microspheres for Yttrium-90 radioembolization treatment of hepatocellular carcinoma
3个月前
已关闭
The coming of age of cyclic peptide drugs: an update on discovery technologies
4个月前
已完结
Consensus statement on safety of combining transarterial radioembolization with 90yttrium microspheres with systemic anticancer agents for the treatment of liver malignancy
4个月前
已完结
皖公网安备34019202002308
